In this plenary session, we will discuss about future perspective on diagnoses and therapies for dyslipidemia.
Finn Waagstein（Sahlgrenska University Hospital, Sweden） Osamu Yamaguchi（Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine） Youji Nagata（Division of Cardiology, Kanazawa University Graduate School of Medicine） Tsunenori Saito（Department of Cardiovascular Medicine, Nippon Medical School） Shouji Matsushima（Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Science） Heart failure (HF) is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood.
Recently published clinical trials involving the addition of niacin or CETP inhibitors failed to prove clinical benefit despite significantly increasing the HDL-C.
From these results the function of HDL and fatty acids are highlighted for assessing risk or response to therapies targeted at HDL.
As a result, the gap between medical spending for the elderly, i.e.
those age 75 and older, of approximately trillion in FY2013 (accounting for 32.7% of the national health expenditure, up 3.7% from the previous year), and the real economy that supports it (nominal GDP: up 0.0% year-on-year) continues to expand.
Cardiovascular diseases have increased in share as the cause of death, accounting for 26.8% of total deaths, with 15.5% being due to heart diseases and 9.0%, to cerebrovascular diseases.
Therefore, meticulous regular follow-up is necessary in ACHD.
In this symposium, we will be focusing on these long-term complications regarding pathophysiology, current status and recent management in ACHD patients.
HF is a leading cause of morbidity and mortality in industrialized countries and is also a growing public health problem, mainly because of aging of the population.
The basic research at the genomic, molecular, cellular, and organ levels has elucidated the pathophysiology of HF.